Halozyme Therapeutics, Inc. (HALO)
100.24
-0.43
(-0.43%)
USD |
NASDAQ |
Nov 13, 16:00
100.20
-0.04
(-0.04%)
After-Hours: 19:59
Halozyme Therapeutics Enterprise Value : 13.65B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 13.65B |
| November 11, 2026 | 13.76B |
| November 10, 2026 | 13.91B |
| November 09, 2026 | 13.90B |
| November 06, 2026 | 13.98B |
| November 05, 2026 | 16.19B |
| November 04, 2026 | 17.03B |
| November 03, 2026 | 16.83B |
| November 02, 2026 | 16.87B |
| October 30, 2026 | 17.09B |
| October 29, 2026 | 17.12B |
| October 28, 2026 | 16.99B |
| October 27, 2026 | 16.82B |
| October 26, 2026 | 16.76B |
| October 23, 2026 | 16.49B |
| October 22, 2026 | 16.37B |
| October 21, 2026 | 16.40B |
| October 20, 2026 | 16.35B |
| October 19, 2026 | 16.13B |
| October 16, 2026 | 16.06B |
| October 15, 2026 | 16.02B |
| October 14, 2026 | 15.49B |
| October 13, 2026 | 14.67B |
| October 12, 2026 | 14.83B |
| October 09, 2026 | 14.76B |
| Date | Value |
|---|---|
| October 08, 2026 | 14.69B |
| October 07, 2026 | 14.80B |
| October 06, 2026 | 14.68B |
| October 05, 2026 | 14.52B |
| October 02, 2026 | 14.69B |
| October 01, 2026 | 14.36B |
| September 30, 2026 | 14.75B |
| September 29, 2026 | 14.64B |
| September 28, 2026 | 14.79B |
| September 25, 2026 | 14.91B |
| September 24, 2026 | 15.06B |
| September 23, 2026 | 14.74B |
| September 22, 2026 | 15.05B |
| September 21, 2026 | 14.63B |
| September 18, 2026 | 14.74B |
| September 17, 2026 | 14.42B |
| September 16, 2026 | 14.28B |
| September 15, 2026 | 14.03B |
| September 14, 2026 | 14.23B |
| September 11, 2026 | 14.14B |
| September 10, 2026 | 14.12B |
| September 09, 2026 | 14.16B |
| September 08, 2026 | 14.27B |
| September 04, 2026 | 14.48B |
| September 03, 2026 | 14.55B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AVITA Medical, Inc. | 538.23M |
| Iovance Biotherapeutics, Inc. | 3.198B |
| Merck & Co., Inc. | 406.57B |
| Neurocrine Biosciences, Inc. | 16.81B |
| TG Therapeutics, Inc. | 10.01B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 247.05M |
| Revenue (Quarterly) | 492.97M |
| Total Expenses (Quarterly) | 245.92M |
| EPS Diluted (Quarterly) | 2.015 |
| Gross Profit Margin (Quarterly) | 77.28% |
| Profit Margin (Quarterly) | 50.11% |
| Earnings Yield | 3.92% |
| Operating Earnings Yield | 8.42% |
| Normalized Earnings Yield | 6.016 |